Role of Nefopam in Rituximab Transfusion Reaction

Nefopam Clinical Trial

Official title:

Role of Nefopam in Rituximab Transfusion Reaction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05648058
• Other study ID #: nefopam with rituximab
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 20, 2022
• Est. completion date: November 20, 2023

Study information

• Verified date: December 2022
• Source: Ministry Of Health / Nineveh Health Directorate
• Contact: fakhraldin marwan
• Phone: 07817639470
• Email: drfakhralin[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

the patients will be taken nefopam ampule 50 mg before rituximab in the first group while the second group will be taken diphenhydramine ampule 10 mg before rituximab in the second group

Description:

the two groups will be taken standard therapy (hydrocortisone vial 100 mg and acetaminophen 1000 mg) 30 min before rituximab

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: November 20, 2023
• Est. primary completion date: October 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18 - 80 years old male and female will be taken rituximab

Exclusion Criteria:

• less than 18 years old more than 80 years old diabetic patients

Related Conditions & MeSH terms

• Nefopam
• Transfusion Reaction

Intervention

Drug:
• Nefopam ampule
nefopam ampule 50 mg
• diphenhydramine ampule
diphenhydramine ampule 10 mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ministry Of Health / Nineveh Health Directorate

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	transfusion reaction	fever, riger, rash, chills, pruritus and bronchospasm	30 min